BRCA1 and breast carcinoma: Extending these findings to a human system, the survival of Polθ- and BRCA1-co-depleted CAL51 human basal breast cancer epithelial cells was improved by low-concentration RAD52 inhibitor or treatment with a low concentration of RAD52 siRNA (Fig. 3j and Supplementary Fig. 4f).